<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypoglycemia in adults with diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypoglycemia in adults with diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypoglycemia in adults with diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip E Cryer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kasia J Lipska, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irl B Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypoglycemia is the most common acute complication of glucose-lowering therapy and is associated with poor outcomes and quality of life in people with type 1 and type 2 diabetes. Hypoglycemia is more common among patients with type 1 diabetes than those with type 2 diabetes and is usually limited to patients with type 2 diabetes treated with specific medication classes (eg, insulin, sulfonylureas, or meglitinides) [<a href="#rid1">1,2</a>]. Reducing the risk of hypoglycemia involves patient education and empowerment, frequent blood glucose monitoring (BGM; usually with fingerstick measurements or continuous glucose monitoring [CGM]), individualized glycemic goals, flexible and rational insulin (and other drug) regimens, and ongoing professional guidance and support.</p><p>The symptoms, risk factors, and treatment of hypoglycemia in adults with diabetes are reviewed in this topic, as are general strategies for hypoglycemia risk reduction. Specific strategies to mitigate the risk of hypoglycemia in the inpatient and ambulatory settings, as well as the physiologic response to hypoglycemia, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/123060.html" rel="external">"Continuous subcutaneous insulin infusion (insulin pump)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1776.html" rel="external">"Treatment of type 2 diabetes mellitus in the older patient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H3417728758"><span class="h1">SYMPTOMS</span><span class="headingEndMark"> — </span>Hypoglycemia causes neurogenic (autonomic) and neuroglycopenic symptoms. Older adults and patients with longstanding diabetes may have more neuroglycopenic than neurogenic manifestations of hypoglycemia.</p><p class="bulletIndent1"><span class="glyph">●</span>The neurogenic symptoms include tremor, palpitations, and anxiety/arousal (catecholamine mediated, adrenergic) and sweating, hunger, and paresthesias (acetylcholine mediated, cholinergic) [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The neuroglycopenic symptoms include dizziness, weakness, drowsiness, delirium, confusion, and, at lower plasma glucose concentrations, seizure and coma [<a href="#rid3">3,4</a>]. Profound, prolonged hypoglycemia can cause brain death if unwitnessed and left untreated, but the vast majority of episodes are reversed after the glucose level is raised. The rare, fatal episodes are generally thought to be the result of ventricular arrhythmia [<a href="#rid4">4</a>].</p><p></p><p>In patients with diabetes, the onset of symptoms of hypoglycemia may occur at glucose levels less than 70 mg/dL (3.9 mmol/L), although the specific value varies between and within individuals over time.</p><p>The lower limit of the laboratory reference range for fasting plasma glucose level in individuals without diabetes is typically 70 mg/dL (3.9 mmol/L). The glycemic thresholds for neurogenic and neuroglycopenic responses shift to higher plasma glucose concentrations in patients with chronic hyperglycemia and to lower plasma glucose concentrations in patients with repeated episodes of hypoglycemia, which may be caused by intensive diabetes treatment [<a href="#rid5">5</a>]. The degree of hypoglycemia at which symptoms arise varies across individuals. Symptoms may be absent because of impaired awareness of hypoglycemia, which is thought to result from reduced sympathoadrenal (predominantly sympathetic neural) responses. These blunted responses may be caused by recent antecedent hypoglycemia, prior exercise, or sleep in patients with diabetes [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus", section on 'Hypoglycemia-associated autonomic failure'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND CLASSIFICATION</span><span class="headingEndMark"> — </span>Hypoglycemia is the result of the interplay between absolute or relative therapeutic insulin excess and compromised physiologic and behavioral defenses against falling plasma glucose concentrations (defective glucose counterregulation and impaired awareness of hypoglycemia). (See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Definition</span><span class="headingEndMark"> — </span>Hypoglycemia in patients with diabetes is defined as all episodes of an abnormally low plasma glucose concentration (with or without symptoms) that expose the individual to harm [<a href="#rid1">1,6</a>]. Although glycemic thresholds that induce symptoms (and counterregulatory responses) vary within and between individuals, professional societies and workgroups generally agree on the following definitions of three levels of hypoglycemia [<a href="#rid6">6-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Level 1 hypoglycemia</strong> – A blood glucose level &lt;70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3 mmol/L) should alert the patient to take action. This glucose threshold approximates the lower limit of the physiologic, nondiabetic fasting range, the normal glycemic threshold for glucose counterregulatory hormone secretion, and the highest antecedent low glucose level reported to reduce sympathoadrenal responses to subsequent hypoglycemia [<a href="#rid1">1</a>]. It should alert the patient to take action such as ingestion of carbohydrate (see <a class="local">'Reversing hypoglycemia'</a> below) or, at the very least, repeated measurements of the glucose level and temporary avoidance of critical tasks such as driving.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Level 2 hypoglycemia</strong> – A blood glucose level &lt;54 mg/dL (3 mmol/L) indicates serious hypoglycemia requiring immediate action [<a href="#rid7">7</a>]. This value identifies an unequivocally low glucose level, one that occurs rarely, if at all, in individuals without diabetes under physiologic conditions and one that should be avoided because of immediate and long-term consequences to the individual. This level of hypoglycemia is typically associated with cognitive impairment [<a href="#rid10">10</a>]. The frequency of detection of a glucose level &lt;54 mg/dL (3 mmol/L) has been recommended for inclusion when reporting hypoglycemia in clinical trials of glucose-lowering drugs [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Level 3 hypoglycemia</strong> – Level 3 hypoglycemia is defined as a hypoglycemic event that requires the assistance of another person to actively administer carbohydrate, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, or other resuscitative actions. Plasma glucose measurements may not be available during such an event, but neurologic recovery attributable to normalization of plasma glucose is considered sufficient evidence that the event was induced by a low plasma glucose concentration.</p><p></p><p>These definitions of hypoglycemia assume accurate and reliable measurement of glucose levels. Blood glucose monitoring (BGM) provides information about capillary glucose levels at a specific point in time. Notably, BGM readings may not be accurate in patients with poor capillary blood flow, such as those with shock, hypothermia, Raynaud phenomenon, or peripheral vascular disease [<a href="#rid11">11,12</a>]. Continuous glucose monitoring (CGM) measures interstitial glucose and therefore provides distinct information from BGM. CGM may be helpful for patients in whom BGM is consistently unreliable. It also may be helpful for capturing time spent in hypoglycemia as well as hypoglycemia missed by BGM, especially during sleep. Although there is no consensus for defining level 1 and 2 hypoglycemia based on CGM data, several studies have used 15 consecutive minutes with sensor glucose values below the respective thresholds (ie, &lt;70 mg/dL [3.9 mmol/L] or &lt;54 mg/dL [3 mmol/L]) for this purpose [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H279391023"><span class="h2">Clinical classification</span><span class="headingEndMark"> — </span>Clinical classification of hypoglycemic events can be helpful for identifying and tracking hypoglycemia:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Documented symptomatic hypoglycemia</strong> – An event during which typical symptoms of hypoglycemia are accompanied by a measured glucose level &lt;70 mg/dL (3.9 mmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic hypoglycemia</strong> – An event not accompanied by typical symptoms of hypoglycemia but with a measured glucose level &lt;70 mg/dL (3.9 mmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probable symptomatic hypoglycemia</strong> – An event during which typical symptoms of hypoglycemia are not accompanied by measurement of the glucose level but resolve after action taken to reverse hypoglycemia (eg, carbohydrate ingestion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudohypoglycemia</strong> – An event during which the person with diabetes reports typical symptoms of hypoglycemia but has a measured glucose level ≥70 mg/dL (3.9 mmol/L).</p><p></p><p class="bulletIndent1">This category reflects the fact that patients with chronic hyperglycemia can experience sympathoadrenal symptoms as glucose levels fall into the physiologic range. (This term is also used to describe artifactually low plasma or serum glucose concentrations due to poor capillary blood flow or continued metabolism of glucose after sample collection due to absence of a glycolysis inhibitor or delayed sample processing.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">MAGNITUDE OF THE PROBLEM</span></p><p class="headingAnchor" id="H6"><span class="h2">Frequency</span></p><p class="headingAnchor" id="H7"><span class="h3">Type 1 diabetes</span><span class="headingEndMark"> — </span>Patients with type 1 diabetes report an average of two to five episodes of severe hypoglycemia (episodes requiring the assistance of another person) per year [<a href="#rid1">1,15,16</a>]. Studies using continuous glucose monitoring (CGM) show much more frequent episodes of clinically important hypoglycemia (&lt;54 mg/dL [3 mmol/L]), ranging from every two to three days to every six days [<a href="#rid13">13,17-19</a>]. Clinically important hypoglycemia detected with CGM is much more common than prior estimates based on self-reported events or fingerstick glucose assessments. Of note, CGM may over-report hypoglycemia, especially in the lower range of normoglycemia, which suggests that the frequency of clinically important hypoglycemia may be overstated with CGM. (See  <a class="medical medical_review" href="/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'Reliability'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Type 2 diabetes</span><span class="headingEndMark"> — </span>Hypoglycemia is substantially less frequent in type 2 diabetes, although patients with type 2 diabetes treated with insulin, a sulfonylurea or a meglitinide are generally at higher risk than those treated with diet or other medications [<a href="#rid1">1,2</a>]. Among the commonly used insulin secretagogues (sulfonylureas, meglitinides), hypoglycemia is most often reported in patients taking long-acting drugs, such as <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a> (glibenclamide) [<a href="#rid20">20</a>], compared with sulfonylureas with lower risk for hypoglycemia (eg, <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a>, <a class="drug drug_general" data-topicid="8491" href="/d/drug information/8491.html" rel="external">glimepiride</a>, and <a class="drug drug_general" data-topicid="8785" href="/d/drug information/8785.html" rel="external">gliclazide</a>) (see  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"</a>). In contrast to insulin and insulin secretagogues, agents that do not cause unregulated hyperinsulinemia (eg, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, alpha-glucosidase inhibitors, thiazolidinediones, glucagon-like peptide 1 [GLP-1] receptor agonists, dual GLP-1 and gastric inhibitory polypeptide [GIP] receptor agonists, dipeptidyl peptidase 4 [DPP-4] inhibitors, and sodium-glucose co-transporter 2 [SGLT2] inhibitors) do not usually cause hypoglycemia [<a href="#rid21">21,22</a>]. However, they increase the risk if used with insulin or an insulin secretagogue [<a href="#rid2">2</a>].</p><p>The frequency of serious, clinically important hypoglycemia in type 2 diabetes, particularly in advanced type 2 diabetes, is uncertain. The frequency of hypoglycemia increases over time as patients approach the insulin-deficient end of the spectrum of type 2 diabetes. In a global observational study, the rate of severe hypoglycemia among insulin-treated patients with type 2 diabetes was 2.5 events per person-year [<a href="#rid16">16</a>].</p><p>Although observational studies suggest that CGM detects higher numbers of hypoglycemic events in insulin-treated patients with type 2 diabetes than reported using fingerstick measurements [<a href="#rid23">23</a>], clinical trial data suggest that hypoglycemia is infrequent in such patients irrespective of glucose monitoring strategy. As an example, in a trial evaluating CGM or usual care (blood glucose monitoring [BGM] at least four times daily) in 158 adults with type 2 diabetes (median duration 17 years) and treated with multiple daily insulin injections, hypoglycemia was infrequent in both groups (eg, percentage of time spent &lt;60 mg/dL [&lt;3.3 mmol/L], 0 percent) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Consequences</span><span class="headingEndMark"> — </span>Recurrent hypoglycemia is a strong risk factor for impaired awareness of hypoglycemia. In turn, impaired awareness of hypoglycemia increases the risk of severe hypoglycemia sixfold in people with type 1 diabetes and 17-fold in individuals with type 2 diabetes who are taking insulin [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H3697637857"><span class="h3">Health-related quality of life</span><span class="headingEndMark"> — </span>Hypoglycemia, particularly nocturnal or severe episodes, has been associated with reduced health-related quality of life [<a href="#rid27">27,28</a>]. Severe hypoglycemia has been associated with diabetes distress and fear of hypoglycemia [<a href="#rid29">29</a>]. In turn, fear of hypoglycemia can lead to behaviors that are detrimental to diabetes management [<a href="#rid30">30</a>]. Nonsevere hypoglycemia may also diminish quality of life. In middle-aged adults (mean age 53.5 years), nonsevere hypoglycemia has been shown to increase time away from work [<a href="#rid31">31</a>]. Recurrent episodes of hypoglycemia may impact driving privileges, employment, and interpersonal relationships [<a href="#rid30">30</a>]. (See <a class="local">'Fear of hypoglycemia'</a> below.)</p><p class="headingAnchor" id="H3198329177"><span class="h3">Health-related outcomes</span><span class="headingEndMark"> — </span>Hypoglycemia is associated with multiple other adverse consequences. Whether hypoglycemia directly causes these adverse outcomes or is a marker of greater vulnerability to these outcomes is not always clear.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality and cardiovascular disease</strong> – Acute hypoglycemic episodes can be life-threatening and account for up to 10 percent of deaths in people with type 1 diabetes under 40 years of age [<a href="#rid32">32</a>]. In clinical trials and observational studies, severe hypoglycemia is associated with a roughly 1.5- to 6-fold increased risk of cardiovascular events and mortality [<a href="#rid33">33-38</a>]. Whether hypoglycemia plays a causal role in cardiovascular disease is unclear, as confounders including comorbid illness may contribute to this observed association. A direct relationship between hypoglycemia and cardiovascular disease, particularly coronary heart disease, has been posited in part based on the biological effects of hypoglycemia, including adverse regulation of sympathoadrenal, immune, and endothelial function [<a href="#rid34">34</a>]. In a meta-analysis of observational studies with bias analysis, comorbid illness alone did not fully explain the association between hypoglycemia and cardiovascular disease [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/1776.html" rel="external">"Treatment of type 2 diabetes mellitus in the older patient", section on 'Avoiding hypoglycemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive impairment and dementia</strong> – The extent to which recurrent hypoglycemia causes cognitive impairment is uncertain and may depend in part on patient age [<a href="#rid1">1,39</a>]. In older adults, severe hypoglycemia has been associated with an increased risk of dementia [<a href="#rid40">40-43</a>]. In turn, older adults with diabetes who develop dementia have a higher risk of hypoglycemia. In younger adults, however, the results from the Diabetes Control and Complications Trial (DCCT; mean age on study entry 27 years) are reassuring. Although the frequency of severe hypoglycemia in the DCCT was &gt;3-fold higher in the intensive treatment group as compared with the conventional treatment group, the two groups did not differ in multiple psychosocial and neurobehavioral parameters measured at 2, 5, 7, and 18 years; furthermore, patients with repeated episodes of hypoglycemia did not perform differently from those who rarely had hypoglycemia [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Falls and fractures</strong> — In frail, older adults, mild episodes of hypoglycemia may lead to episodes of dizziness or weakness, increasing the risk of falls and fracture [<a href="#rid46">46,47</a>]. Severe hypoglycemia has also been associated with increased risk of falls and fractures in both type 1 and type 2 diabetes [<a href="#rid48">48-50</a>]. (See  <a class="medical medical_review" href="/d/html/1776.html" rel="external">"Treatment of type 2 diabetes mellitus in the older patient", section on 'Avoiding hypoglycemia'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">RISK FACTORS FOR HYPOGLYCEMIA</span><span class="headingEndMark"> — </span>The precipitants of hypoglycemia are rarely documented in observational studies or clinical trials. In more than half of hypoglycemic events, a direct precipitant is not clearly identified [<a href="#rid51">51,52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct precipitants</strong> – In studies that evaluated precipitating events of hypoglycemia, the following factors were most commonly cited [<a href="#rid51">51-54</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed or missed meals, or low carbohydrate content of meals</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Excessive physical activity</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medication errors (eg, miscalculated doses, wrong insulin type)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Overcorrection of hyperglycemia (eg, intentionally taking additional insulin)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Illness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient- and treatment-related factors</strong> – Beyond the immediate precipitants of hypoglycemic events, multiple patient- and treatment-related factors can increase the risk of hypoglycemia. Patient-related risk factors include the following [<a href="#rid1">1,2,55-61</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypoglycemia-associated autonomic failure (including the syndromes of impaired awareness of hypoglycemia and deficient glucose counterregulation)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of severe or nonsevere hypoglycemia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Longer duration of diabetes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older age</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol ingestion</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dementia or cognitive impairment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malnutrition with glycogen depletion</p><p></p><p class="bulletIndent1">Treatment-related risk factors for iatrogenic hypoglycemia include insulin therapy in patients with either type 1 or type 2 diabetes and sulfonylurea or meglitinide therapy in patients with type 2 diabetes [<a href="#rid2">2,62</a>]. Multiple studies have demonstrated that the risk of hypoglycemia increases with the duration of insulin use [<a href="#rid61">61,63</a>]. (See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Hypoglycemia'</a> and  <a class="medical medical_review" href="/d/html/1786.html" rel="external">"Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus", section on 'Hypoglycemia'</a>.)</p><p></p><p class="bulletIndent1">Randomized trials in type 1 [<a href="#rid64">64,65</a>] and type 2 [<a href="#rid66">66-68</a>] diabetes have consistently demonstrated that patients treated to lower glycated hemoglobin (A1C) levels (to reduce long-term microvascular complications) have two- to threefold higher rates of hypoglycemia. However, in observational studies, the relationship between A1C level and hypoglycemia is not linear. For example, in the Type 1 Diabetes Exchange Clinic Registry, the risk of severe hypoglycemia that required the assistance of another person was lowest among those with A1C levels of 7 to 7.5 percent and higher in those with A1C levels &lt;7 or &gt;7.5 percent [<a href="#rid69">69</a>]. Similarly, the relationship between A1C and severe hypoglycemia in patients with type 2 diabetes appears to be U-shaped, with greater risk at both low and high A1C levels  (<a class="graphic graphic_figure graphicRef59452" href="/d/graphic/59452.html" rel="external">figure 1</a>) [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors</strong> — Finally, other important factors have been associated with hypoglycemia. These include [<a href="#rid72">72-74</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Food insecurity</p><p class="bulletIndent2"><span class="glyph">•</span>Limited health literacy</p><p class="bulletIndent2"><span class="glyph">•</span>Low socioeconomic status</p><p></p><p class="headingAnchor" id="H18"><span class="h1">STRATEGIES TO MANAGE HYPOGLYCEMIA</span><span class="headingEndMark"> — </span>Our approach to the management of hypoglycemia outlined below is largely consistent with the American Diabetes Association (ADA) Standards of Care and the Endocrine Society Clinical Practice Guidelines [<a href="#rid6">6,9,75</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p>Strategies to reduce the risk of hypoglycemia in the ambulatory setting are reviewed below. The approach to mitigating hypoglycemia in the inpatient setting is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1770.html" rel="external">"Management of diabetes mellitus in hospitalized patients"</a>.)</p><p class="headingAnchor" id="H2082011130"><span class="h2">General approach to reduce risk</span><span class="headingEndMark"> — </span>The prevention of hypoglycemia involves identifying precipitants and risk factors contributing to hypoglycemia, addressing these (when possible), and tailoring treatment regimens to reduce risk. At each visit, the provider should inquire about any:</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of symptoms consistent with hypoglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Low measured glucose levels</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes requiring the assistance of another person</p><p></p><p>All available blood glucose monitoring (BGM) or continuous glucose monitoring (CGM) data should be reviewed to determine the frequency and details (eg, time of day, severity) of any documented episodes of hypoglycemia. Insulin and other glucose-lowering medications should be adjusted based on glucose patterns with focus on reducing hypoglycemia, which sometimes may require adjusting the target glucose and A1C levels. Any clear precipitants (eg, exercise, overcorrection of hyperglycemia) or other risk factors (eg, cognitive impairment, food insecurity) should be specifically addressed.</p><p>Reducing the risk of hypoglycemia involves application of the following principles [<a href="#rid1">1,2,76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient education and empowerment</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent monitoring of glucose levels (with fingerstick measurements or CGM)</p><p class="bulletIndent1"><span class="glyph">●</span>Individualized glycemic goals</p><p class="bulletIndent1"><span class="glyph">●</span>Flexible and rational regimens for insulin and other drugs</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing professional guidance and support</p><p></p><p>In a meta-analysis of 43 studies (randomized trials and observational studies), both educational interventions (eg, flexible insulin therapy, behavioral techniques) and technological interventions (continuous subcutaneous insulin infusion [CSII], CGM, sensor-augmented pump) reduced severe hypoglycemia and improved glycemic management in patients with type 1 diabetes [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H4056936934"><span class="h3">Patient education</span><span class="headingEndMark"> — </span>There is increasing evidence that structured patient education focused on implementation of flexible insulin therapy can reduce the incidence of severe hypoglycemia in patients with type 1 diabetes [<a href="#rid6">6,78-81</a>]. Although data are sparse, similar results could reasonably be expected for patients with type 2 diabetes. Patients should be taught to adjust their medications, meal plans, and exercise based on glucose patterns. Clinicians should review how to treat (but not overtreat) evolving hypoglycemia with oral carbohydrate ingestion or <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>. In addition, close associates, such as a spouse or a partner, should be taught to recognize severe hypoglycemia and administer treatment with glucagon. (See <a class="local">'Reversing hypoglycemia'</a> below.)</p><p>Regular glucose monitoring is critical for glycemic management in patients with type 1 diabetes as well as insulin-treated patients with type 2 diabetes. CGM is usually used in type 1 diabetes, but some evidence suggests that many insulin-treated patients with type 2 diabetes may benefit as well [<a href="#rid82">82,83</a>]. The use of CGM can help identify glycemic patterns and hypoglycemia [<a href="#rid84">84</a>]. Alternatively, patients may perform BGM before and two to three hours after each meal, at bedtime, in the middle of the night, and before and after exercise. For patients with diabetes who may have asymptomatic hypoglycemia due to repeated episodes of hypoglycemia and/or impaired awareness of hypoglycemia, intermittent use of CGM may be valuable for the detection and management of hypoglycemia. (See  <a class="medical medical_review" href="/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'CGM systems'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Glycemic targets</span><span class="headingEndMark"> — </span>Glycemic management can reduce the risks for retinopathy, nephropathy, and neuropathy in both type 1 and type 2 diabetes and may decrease the risk for cardiovascular disease. Target A1C levels in patients with type 1 and type 2 diabetes should be individualized and based on patient preferences, balancing the reduction in microvascular complications with the risk of hypoglycemia and burden and cost of therapy [<a href="#rid85">85-88</a>]. Less stringent treatment goals may be appropriate for patients with a history of severe hypoglycemia, risk factors for hypoglycemia, or limited life expectancies, as well as very young children or older adults and individuals with comorbid conditions. De-escalation of therapy in some individuals may be appropriate. However, given that severe hypoglycemia is common in patients with poor glycemia, simply relaxing the glycemic target may not reduce hypoglycemia risk  (<a class="graphic graphic_figure graphicRef59452" href="/d/graphic/59452.html" rel="external">figure 1</a>).</p><p>Glycemic goals are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'</a> and  <a class="medical medical_review" href="/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus", section on 'Glycemic targets'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Glucose-lowering regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1 diabetes</strong> – More than half of episodes of iatrogenic hypoglycemia, including severe hypoglycemia, occur during the night [<a href="#rid2">2,89</a>]. Nocturnal hypoglycemia in type 1 diabetes is less common in individuals using rapid-acting insulin analogs (lispro, aspart, glulisine) rather than <a class="drug drug_general" data-topicid="9030" href="/d/drug information/9030.html" rel="external">regular insulin</a> before meals and slightly lower in individuals using long-acting insulin analogs (glargine, detemir, degludec) rather than NPH as the basal insulin. Nocturnal and/or fasting hypoglycemia warrants assessment not only of the basal insulin dose but also of any bedtime insulin boluses for food and/or correction of hyperglycemia. Patients also should be queried about exercise patterns and alcohol use. (See  <a class="medical medical_review" href="/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus", section on 'Choosing basal/prandial insulin'</a>.)</p><p></p><p class="bulletIndent1">Although many clinicians believe CSII in type 1 diabetes reduces hypoglycemia, in patients at comparable A1C levels, CSII has not consistently reduced hypoglycemia relative to a basal-bolus regimen with insulin analogs [<a href="#rid90">90,91</a>]. However, CSII in conjunction with CGM (including sensor-augmented insulin pump therapy and hybrid closed-loop systems) can reduce time in hypoglycemia. The trials that demonstrate this benefit are reviewed separately. (See  <a class="medical medical_review" href="/d/html/123060.html" rel="external">"Continuous subcutaneous insulin infusion (insulin pump)", section on 'Sensor-augmented insulin pump'</a> and  <a class="medical medical_review" href="/d/html/123060.html" rel="external">"Continuous subcutaneous insulin infusion (insulin pump)", section on 'Insulin only, partially automated system'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 2 diabetes</strong> – In patients with type 2 diabetes, clinicians should consider using medications that are not associated with hypoglycemia whenever possible. In a single-arm study of older patients with type 2 diabetes on multiple daily insulin injections, simplification to once-daily basal insulin with or without noninsulin medications reduced hypoglycemia without compromising glycemic management [<a href="#rid92">92</a>]. Choice of insulin may also impact hypoglycemia risk; for example, long-acting insulin analogs may reduce nocturnal hypoglycemia (but not always total hypoglycemia) compared with NPH. (See  <a class="medical medical_review" href="/d/html/1801.html" rel="external">"Insulin therapy in type 2 diabetes mellitus", section on 'Choice of basal insulin'</a>.)</p><p></p><p class="headingAnchor" id="H3078461653"><span class="h2">Specific settings</span></p><p class="headingAnchor" id="H22"><span class="h3">Impaired awareness of hypoglycemia</span><span class="headingEndMark"> — </span>In patients with a history of impaired awareness of hypoglycemia, a two- to three-week period of scrupulous avoidance of hypoglycemia is advisable since that often restores awareness [<a href="#rid93">93-99</a>]. That can be accomplished by more intensive professional involvement (eg, by telephone); in practice, it may require higher glycemic goals in the short term. Blood glucose awareness training, focused on cultivating patient awareness and anticipation of hypoglycemia, has been reported to both reduce hypoglycemic episodes and improve detection of hypoglycemia [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H24"><span class="h3">Exercise-induced hypoglycemia</span><span class="headingEndMark"> — </span>Exercise-induced hypoglycemia can occur during, shortly after, or many hours after exercise, and therefore, patients should remain vigilant for its occurrence, utilizing frequent BGM or CGM.</p><p>Measures to reduce early post-exercise hypoglycemia include interspersing brief episodes of intense exercise (which tends to raise plasma glucose concentrations), adding carbohydrate ingestion (eg, 1 g/kg/h), and reducing insulin doses [<a href="#rid101">101</a>]. In one study in patients with type 1 diabetes, a subcutaneous injection of mini-dose (150 mcg) <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> prevented exercise-induced hypoglycemia without producing hyperglycemia [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/1777.html" rel="external">"Exercise guidance in adults with diabetes mellitus", section on 'Glycemic management during exercise'</a>.)</p><p>Exercise increases glucose utilization by muscle and, therefore, can cause hypoglycemia in patients with insulin-deficient diabetes who have near-normal or moderately elevated plasma glucose levels at the start of exercise [<a href="#rid2">2,103-106</a>]. In addition, exercise, like hypoglycemia, can shift the glycemic threshold for the sympathoadrenal response to subsequent hypoglycemia to a lower plasma glucose concentration hours later. This shift causes defective glucose counterregulation by reducing epinephrine responses in the setting of absent insulin and <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> responses. It also causes impaired awareness of hypoglycemia by reducing symptom responses. (See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus", section on 'Exercise'</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Fear of hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia can be a frightening, unpleasant, and potentially lethal complication of diabetes, and therefore, concerns about hypoglycemia are understandable. At its best, this concern should prompt patients to be aware of early symptoms and to ingest carbohydrate before symptoms progress. Fear of hypoglycemia is defined as an excessive worry/discomfort that interferes with diabetes management through behavioral avoidance and distress. In one survey, patients who had a frightening episode of severe hypoglycemia in the previous year often became so fearful that they kept their blood glucose excessively high for several months afterwards [<a href="#rid107">107</a>]. As a result, it is important to explore the patient's experience with hypoglycemia, particularly before intensifying insulin or other glucose-lowering therapy. Educational strategies need to focus on how to help the patient manage the risk of hypoglycemia. Blood glucose awareness training can reduce fear of hypoglycemia [<a href="#rid108">108</a>].</p><p class="headingAnchor" id="H2131196832"><span class="h3">Severe, intractable hypoglycemia</span><span class="headingEndMark"> — </span>Patients with severe, intractable hypoglycemia may be candidates for pancreas transplantation. Successful pancreas transplantation can result in independence from exogenous insulin therapy and improvements in glucose metabolism, A1C, acute insulin responses to intravenous (IV) glucose, and counterregulatory responses of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> and epinephrine to insulin-induced hypoglycemia. Islet transplantation, an evolving technology, can also result in insulin independence and reduce the incidence of hypoglycemia. Islet transplantation can be performed currently only within the context of a clinical research study. (See  <a class="medical medical_review" href="/d/html/1767.html" rel="external">"Pancreas and islet transplantation in diabetes mellitus", section on 'Indications for transplantation'</a>.)</p><p class="headingAnchor" id="H423921124"><span class="h3">Older patients</span><span class="headingEndMark"> — </span>Older patients with diabetes have increased vulnerability to hypoglycemia. Many older adults experience delayed recognition of hypoglycemia and suffer more serious consequences of hypoglycemic events. Strategies for mitigating the risk of hypoglycemia in older adults are similar to those employed for other patients with diabetes. The treatment of diabetes in older patients in reviewed separately. (See <a class="local">'Strategies to manage hypoglycemia'</a> above and  <a class="medical medical_review" href="/d/html/1776.html" rel="external">"Treatment of type 2 diabetes mellitus in the older patient", section on 'Avoiding hypoglycemia'</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">REVERSING HYPOGLYCEMIA</span><span class="headingEndMark"> — </span>The goal of hypoglycemia treatment is to restore a normal plasma glucose concentration by providing dietary or parenteral carbohydrate (specifically glucose), or, in cases of severe hypoglycemia, by administering <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> to stimulate hepatic glucose production. In order to treat early symptoms of hypoglycemia, patients should be certain that fast-acting carbohydrate (such as glucose tablets, hard candy, or sweetened fruit juice) is available at all times, although treatment with glucose tablets is most consistently effective  (<a class="graphic graphic_table graphicRef71872" href="/d/graphic/71872.html" rel="external">table 1</a>) [<a href="#rid109">109</a>]. Patients with type 1 diabetes and those with type 2 diabetes at high risk for severe hypoglycemia should be prescribed glucagon. (See <a class="local">'Level 3 hypoglycemia (requiring assistance)'</a> below.)</p><p class="headingAnchor" id="H644786849"><span class="h2">Level 1 hypoglycemia (&lt;70 but ≥54 mg/dL)</span><span class="headingEndMark"> — </span>When glucose monitoring reveals a glucose level &lt;70 mg/dL (3.9 mmol/L), patients with drug-treated diabetes should take action. Options include repeating the measurement within 15 to 60 minutes (depending on the setting), avoiding critical tasks such as driving, ingesting carbohydrates, and adjusting the treatment regimen [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H28"><span class="h2">Level 2 hypoglycemia (&lt;54 mg/dL)</span><span class="headingEndMark"> — </span>Patients with level 2 hypoglycemia (glucose level &lt;54 mg/dL [3 mmol/L]) should ingest 15 to 20 grams of fast-acting carbohydrate  (<a class="graphic graphic_table graphicRef71872" href="/d/graphic/71872.html" rel="external">table 1</a>), which is usually sufficient to raise the blood glucose into a safe range without inducing hyperglycemia. Patients should be instructed to retest after 15 minutes. If the glucose remains &lt;70 mg/dL (3.9 mmol/L), repeat treatment may be necessary. Acute treatment can be followed by long-acting carbohydrate (a meal or a snack) to prevent recurrent symptoms.</p><p>In patients using insulin or an insulin secretagogue in combination with an alpha-glucosidase inhibitor (<a class="drug drug_general" data-topicid="9219" href="/d/drug information/9219.html" rel="external">acarbose</a>, <a class="drug drug_general" data-topicid="9538" href="/d/drug information/9538.html" rel="external">miglitol</a>, voglibose), only pure glucose (eg, glucose tablets) should be used to treat symptomatic hypoglycemia. Other forms of carbohydrates, such as table sugar (sucrose), will be less effective in raising blood sugar as alpha-glucosidase inhibitors slow digestion of disaccharides.</p><p class="headingAnchor" id="H29"><span class="h2">Level 3 hypoglycemia (requiring assistance)</span><span class="headingEndMark"> — </span>Severe hypoglycemia requires the assistance of another person to actively administer carbohydrate, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, or other resuscitative actions.</p><p class="headingAnchor" id="H4098654329"><span class="h3">With IV access</span><span class="headingEndMark"> — </span>Hospitalized patients can usually be treated quickly with 25 g of 50 percent glucose (dextrose) administered intravenously (IV).</p><p class="headingAnchor" id="H3996817014"><span class="h3">Without IV access</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucagon</strong><strong> available</strong> – For the treatment of hypoglycemia in a person with impaired consciousness and no established IV access, we suggest the immediate administration of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, rather than waiting to establish IV access. Administration of glucagon (subcutaneous, intramuscular, or nasal) will usually lead to recovery of consciousness within approximately 15 minutes, although it may be followed by marked nausea or even vomiting. To prevent these side effects, the glucagon dose should be followed promptly by oral intake of concentrated carbohydrates, ideally immediately upon the patient's emergence from impaired consciousness and before the development of nausea.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">Glucagon</a> administration requires that the glucagon be readily accessible and that a relative or friend can recognize hypoglycemia and administer the glucagon appropriately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intranasal </strong><strong>glucagon</strong> – Intranasal <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> can be delivered by placing the tip of the device in one nostril and depressing a small plunger that discharges the powder into the nostril without need for inhalation or other cooperation from the patient [<a href="#rid111">111</a>]. In a randomized, crossover trial comparing intranasal (3 mg) and intramuscular (1 mg) glucagon in 77 patients with type 1 diabetes and hypoglycemia (induced in a controlled setting by insulin administration), successful reversal of hypoglycemia occurred in 98.7 and 100 percent of intranasal glucagon and intramuscular glucagon treatments, respectively [<a href="#rid112">112</a>]. Mean time to success (glucose ≥70 mg/dL [3.9 mmol/L] or ≥20 mg/dL [1.1 mmol/L] from the glucose nadir) was slightly longer for intranasal than intramuscular administration (16 versus 13 minutes).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable, liquid </strong><strong>glucagon</strong> – <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">Glucagon</a> (or glucagon analog) can be administered using a prefilled syringe, an auto-injector pen, or a syringe kit with a single-dose vial, all of which contain a fixed-dose, stable liquid glucagon preparation that does not require reconstitution [<a href="#rid113">113</a>]. In trials in patients with type 1 diabetes, the successful reversal of hypoglycemia was similar in patients receiving 1 mg of stable liquid glucagon, 1 mg of reconstituted glucagon, or 0.6 mg of glucagon receptor agonist (<a class="drug drug_general" data-topicid="131164" href="/d/drug information/131164.html" rel="external">dasiglucagon</a>) [<a href="#rid114">114-119</a>]. Small doses (mini-doses) of stable, liquid glucagon that may be repeated if necessary are also in development [<a href="#rid120">120,121</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reconstituted </strong><strong>glucagon</strong> – <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">Glucagon</a> lyophilized powder requires reconstitution (mixing the powder with the diluent) immediately before use. It is administered (1 mg) either subcutaneously or intramuscularly. For caregivers who are not medical professionals, the reconstitution process may be challenging in an emergency setting. Consequently, glucagon preparations that do not require reconstitution are preferred for outpatient use [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucagon</strong><strong> not available</strong> – There are no efficacy or safety data to guide the management of severe hypoglycemia (while awaiting emergency personnel) in patients with impaired consciousness and no immediate access to <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> or <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a>. In a study of normoglycemic volunteers, the buccal absorption of glucose was minimal [<a href="#rid122">122</a>]. Therefore, some experts would not administer buccal or sublingual preparations due to concern about aspiration. In the absence of other options for such patients, other experts, including some UpToDate authors and editors, suggest that while awaiting emergency personnel, family members squeeze a glucose gel (eg, Insta-Glucose) or cake frosting in the space between the teeth and buccal mucosa, keeping the patient's head tilted slightly to the side. If a glucose gel or cake frosting is unavailable, some advocate sprinkling table sugar under the tongue as table sugar has been reported to raise plasma glucose concentrations to some extent in ill children with malaria [<a href="#rid123">123,124</a>].</p><p></p><p class="headingAnchor" id="H1262186260"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>The glycemic response to IV glucose and <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> is transient. Therefore, effective initial treatment of hypoglycemia often must be followed by a continuous infusion of glucose (or food if the patient is able to eat). Further treatment and disposition vary depending on the class of agent causing the toxicity and the severity of symptoms. Sulfonylurea-caused hypoglycemia may be particularly long lasting or recurrent since the effects of sulfonylureas or their metabolites may continue to stimulate insulin secretion after initial carbohydrate treatment. (See  <a class="medical medical_review" href="/d/html/308.html" rel="external">"Sulfonylurea agent poisoning", section on 'Management'</a>.)</p><p>There is little experience in treating "overdoses" of the newest longer-acting analogs, such as degludec or U-300 glargine; however, the durable effects of these insulins suggest that observation, continuous glucose monitoring (CGM), and prolonged treatment may be required.</p><p class="headingAnchor" id="H4256292693"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112842.html" rel="external">"Society guideline links: Hypoglycemia in adults"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15401.html" rel="external">"Patient education: Type 1 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15402.html" rel="external">"Patient education: Type 2 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15596.html" rel="external">"Patient education: Low blood sugar in people with diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1736.html" rel="external">"Patient education: Type 1 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1743.html" rel="external">"Patient education: Type 2 diabetes: Overview (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/1742.html" rel="external">"Patient education: Hypoglycemia (low blood glucose) in people with diabetes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Hypoglycemia causes neurogenic (eg, tremor, palpitations, and diaphoresis) and neuroglycopenic (eg, dizziness, weakness, delirium, and confusion) symptoms. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Hypoglycemia in patients with diabetes can be defined as all episodes of an abnormally low plasma glucose concentration (with or without symptoms) that expose the individual to harm. Level 1 hypoglycemia is defined as blood glucose &lt;70 mg/dL (3.9 mmol/L), and level 2 hypoglycemia is defined as blood glucose &lt;54 mg/dL (3 mmol/L). Severe hypoglycemia requires the assistance of another person. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for hypoglycemia</strong> – The direct precipitants of hypoglycemia may not always be identified but most commonly include delayed or missed meals, excessive physical activity, or medication errors. Clinical risk factors for hypoglycemia include hypoglycemia-associated autonomic failure (both impaired awareness of hypoglycemia and defective glucose counterregulation), a history of severe hypoglycemia, a long duration of diabetes, older age, dementia, chronic kidney disease, and malnutrition. Poor glycemic management (ie, chronic hyperglycemia) does not reduce the risk of hypoglycemia. (See <a class="local">'Risk factors for hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach to reduce risk of hypoglycemia</strong> – The prevention of hypoglycemia involves assessing for precipitants and risk factors and addressing them through structured education, changes in the treatment regimen, or changes in glycemic targets when appropriate. (See <a class="local">'General approach to reduce risk'</a> above and <a class="local">'Glucose-lowering regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient education</strong> – Patients should be taught and empowered to adjust their insulin doses based on glucose patterns, meal plans, and planned exercise. Clinicians should review how to treat (but not overtreat) evolving hypoglycemia with oral carbohydrate or <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>. In addition, close associates or caregivers should be taught to recognize severe hypoglycemia and treat it with glucagon. Patients should be cautioned to be especially vigilant following an episode of hypoglycemia since both recognition of hypoglycemia and the attendant counterregulatory response will be impaired in the short term. (See <a class="local">'Patient education'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjustment of glycemic targets</strong> – We consider higher glycated hemoglobin (A1C) target values for patients with one or more previous episodes of severe hypoglycemia, risk factors for hypoglycemia, or little expected benefit from tighter glycemic management. If stringent glycemic management appears to contribute to hypoglycemic events, we continually reevaluate with the patient whether the benefits of improved blood glucose management outweigh the risk of hypoglycemia. (See <a class="local">'Glycemic targets'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Changes in the treatment regimen</strong> – In patients with type 1 diabetes, sensor-augmented insulin pump therapy and hybrid closed-loop systems can reduce time in hypoglycemia. In patients with type 2 diabetes, clinicians should consider using medications that are not associated with hypoglycemia whenever possible and simplifying or de-escalating insulin regimens. (See <a class="local">'Glucose-lowering regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversing hypoglycemia</strong> – We routinely check that the patient's blood glucose monitoring (BGM) equipment is accurately calibrated and that the patient has filled a <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> prescription within the past year. We also continually counsel patients about staying vigilant and keeping fast-acting carbohydrate readily available. (See <a class="local">'Reversing hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Level 1 hypoglycemia (&lt;70 mg/dL but ≥54 mg/dL)</strong> – For a person treated with insulin, a sulfonylurea, or a meglitinide, we suggest the individual take action when glucose monitoring reveals a glucose level &lt;70 mg/dL (3.9 mmol/L) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include repeating the measurement in the near term, avoiding critical tasks such as driving, ingesting carbohydrates, and adjusting the treatment regimen. (See <a class="local">'Level 1 hypoglycemia (&lt;70 but ≥54 mg/dL)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Level 2 hypoglycemia (&lt;54 mg/dL)</strong> – Patients with glucose levels &lt;54 mg/dL (3 mmol/L) should take immediate action to reverse hypoglycemia by ingesting carbohydrates. Fifteen to 20 grams of oral glucose is typically sufficient  (<a class="graphic graphic_table graphicRef71872" href="/d/graphic/71872.html" rel="external">table 1</a>). Glucose may be ingested in the form of tablets, juice, soda, hard candies, or crackers  (<a class="graphic graphic_table graphicRef71872" href="/d/graphic/71872.html" rel="external">table 1</a>). Patients should retest glucose after 15 minutes and re-treat if the glucose level is not ≥70 mg/dL (3.9 mmol/L). (See <a class="local">'Level 2 hypoglycemia (&lt;54 mg/dL)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Level 3 hypoglycemia (requiring assistance)</strong> – For patients with impaired consciousness and established intravenous (IV) access (typically in a hospital), <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a> (25 g of 50 percent glucose [dextrose]) can be administered to treat hypoglycemia. (See <a class="local">'Level 3 hypoglycemia (requiring assistance)'</a> above.)</p><p></p><p class="bulletIndent2">For the treatment of hypoglycemia in a person with impaired consciousness and without established IV access, we suggest the immediate administration of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, rather than waiting to establish IV access (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The usual dose is 3 mg given intranasally or 0.5 to 1 mg given as a subcutaneous or intramuscular injection. Glucagon formulations that do not require reconstitution are preferred for outpatient use. Education and training are necessary for clinicians, family, and other caregivers on the recognition and treatment of severe hypoglycemia, including the use of glucagon. (See <a class="local">'Level 3 hypoglycemia (requiring assistance)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring initial treatment</strong> – The glycemic response to IV glucose and <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> is transient. Therefore, effective initial treatment of hypoglycemia often needs to be followed by a continuous infusion of glucose (or food if the patient can eat). Further treatment and disposition depend on the class of agent causing the toxicity and the severity of symptoms. (See <a class="local">'Monitoring'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013; 98:1845.</a></li><li class="breakAll">Cryer PE. Hypoglycemia in Diabetes. Pathophysiology, Prevalence, and Prevention, 3rd ed. American Diabetes Association. Alexandria 2016</li><li><a class="nounderline abstract_t">Hepburn DA, Deary IJ, Frier BM, et al. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care 1991; 14:949.</a></li><li><a class="nounderline abstract_t">Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007; 117:868.</a></li><li><a class="nounderline abstract_t">Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988; 37:901.</a></li><li><a class="nounderline abstract_t">McCall AL, Lieb DC, Gianchandani R, et al. Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2023; 108:529.</a></li><li><a class="nounderline abstract_t">International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40:155.</a></li><li><a class="nounderline abstract_t">Agiostratidou G, Anhalt H, Ball D, et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40:1622.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S111.</a></li><li><a class="nounderline abstract_t">Verhulst CEM, Fabricius TW, Nefs G, et al. Consistent Effects of Hypoglycemia on Cognitive Function in People With or Without Diabetes. Diabetes Care 2022; 45:2103.</a></li><li><a class="nounderline abstract_t">El Khoury M, Yousuf F, Martin V, Cohen RM. Pseudohypoglycemia: a cause for unreliable finger-stick glucose measurements. Endocr Pract 2008; 14:337.</a></li><li><a class="nounderline abstract_t">Slater-MacLean L, Cembrowski G, Chin D, et al. Accuracy of glycemic measurements in the critically ill. Diabetes Technol Ther 2008; 10:169.</a></li><li><a class="nounderline abstract_t">Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections. Diabetes Ther 2017; 8:947.</a></li><li><a class="nounderline abstract_t">Russell SJ, Beck RW. Design Considerations for Artificial Pancreas Pivotal Studies. Diabetes Care 2016; 39:1161.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard U, Thorsteinsson B. Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls. Curr Diab Rep 2017; 17:131.</a></li><li><a class="nounderline abstract_t">Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab 2016; 18:907.</a></li><li><a class="nounderline abstract_t">Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018; 391:1367.</a></li><li><a class="nounderline abstract_t">Agesen RM, Kristensen PL, Beck-Nielsen H, et al. Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial. Diabetes Technol Ther 2018; 20:247.</a></li><li><a class="nounderline abstract_t">Forlenza GP, Li Z, Buckingham BA, et al. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018; 41:2155.</a></li><li><a class="nounderline abstract_t">Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30:389.</a></li><li><a class="nounderline abstract_t">Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303:1410.</a></li><li><a class="nounderline abstract_t">Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159:262.</a></li><li><a class="nounderline abstract_t">Pazos-Couselo M, García-López JM, González-Rodríguez M, et al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes 2015; 39:428.</a></li><li><a class="nounderline abstract_t">Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med 2017; 167:365.</a></li><li><a class="nounderline abstract_t">Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008; 25:501.</a></li><li><a class="nounderline abstract_t">Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract 2010; 87:64.</a></li><li><a class="nounderline abstract_t">Harris S, Mamdani M, Galbo-Jørgensen CB, et al. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can J Diabetes 2014; 38:45.</a></li><li><a class="nounderline abstract_t">Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013; 11:90.</a></li><li><a class="nounderline abstract_t">Chatwin H, Broadley M, Speight J, et al. The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: A systematic review. Diabetes Res Clin Pract 2021; 174:108752.</a></li><li><a class="nounderline abstract_t">Amiel SA. The consequences of hypoglycaemia. Diabetologia 2021; 64:963.</a></li><li><a class="nounderline abstract_t">Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, et al. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ 2013; 16:1453.</a></li><li><a class="nounderline abstract_t">Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012; 35:1814.</a></li><li><a class="nounderline abstract_t">International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 2019; 7:385.</a></li><li><a class="nounderline abstract_t">Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347:f4533.</a></li><li><a class="nounderline abstract_t">Lee AK, Warren B, Lee CJ, et al. The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. Diabetes Care 2018; 41:104.</a></li><li><a class="nounderline abstract_t">Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410.</a></li><li><a class="nounderline abstract_t">Goto A, Goto M, Terauchi Y, et al. Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. J Am Heart Assoc 2016; 5:e002875.</a></li><li><a class="nounderline abstract_t">Khunti K, Davies M, Majeed A, et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015; 38:316.</a></li><li><a class="nounderline abstract_t">Li W, Huang E, Gao S. Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review. J Alzheimers Dis 2017; 57:29.</a></li><li><a class="nounderline abstract_t">Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 2013; 173:1300.</a></li><li><a class="nounderline abstract_t">Chaytor NS, Barbosa-Leiker C, Ryan CM, et al. Clinically significant cognitive impairment in older adults with type 1 diabetes. J Diabetes Complications 2019; 33:91.</a></li><li><a class="nounderline abstract_t">Han E, Han KD, Lee BW, et al. Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study. J Clin Endocrinol Metab 2022; 107:e1976.</a></li><li><a class="nounderline abstract_t">Whitmer RA, Gilsanz P, Quesenberry CP, et al. Association of Type 1 Diabetes and Hypoglycemic and Hyperglycemic Events and Risk of Dementia. Neurology 2021; 97:e275.</a></li><li><a class="nounderline abstract_t">Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356:1842.</a></li><li><a class="nounderline abstract_t">Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996; 124:379.</a></li><li><a class="nounderline abstract_t">Arnaud M, Pariente A, Bezin J, et al. Risk of Serious Trauma with Glucose-Lowering Drugs in Older Persons: A Nested Case-Control Study. J Am Geriatr Soc 2018; 66:2086.</a></li><li><a class="nounderline abstract_t">Hidayat K, Fang QL, Shi BM, Qin LQ. Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies. Osteoporos Int 2021; 32:1693.</a></li><li><a class="nounderline abstract_t">Lee AK, Juraschek SP, Windham BG, et al. Severe Hypoglycemia and Risk of Falls in Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2020; 43:2060.</a></li><li><a class="nounderline abstract_t">Shah VN, Wu M, Foster N, et al. Severe hypoglycemia is associated with high risk for falls in adults with type 1 diabetes. Arch Osteoporos 2018; 13:66.</a></li><li><a class="nounderline abstract_t">Komorita Y, Minami M, Maeda Y, et al. Prevalence of bone fracture and its association with severe hypoglycemia in Japanese patients with type 1 diabetes. BMJ Open Diabetes Res Care 2021; 9.</a></li><li><a class="nounderline abstract_t">Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014; 174:678.</a></li><li><a class="nounderline abstract_t">Cahn A, Mosenzon O, Bhatt DL, et al. Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study. Diabetes Obes Metab 2017; 19:1045.</a></li><li><a class="nounderline abstract_t">Mitchell BD, Vietri J, Zagar A, et al. Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c. BMC Endocr Disord 2013; 13:59.</a></li><li><a class="nounderline abstract_t">Bonds DE, Miller ME, Dudl J, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord 2012; 12:5.</a></li><li><a class="nounderline abstract_t">Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013; 369:362.</a></li><li><a class="nounderline abstract_t">Henriksen MM, Andersen HU, Thorsteinsson B, Pedersen-Bjergaard U. Hypoglycemic Exposure and Risk of Asymptomatic Hypoglycemia in Type 1 Diabetes Assessed by Continuous Glucose Monitoring. J Clin Endocrinol Metab 2018; 103:2329.</a></li><li><a class="nounderline abstract_t">Karter AJ, Warton EM, Lipska KJ, et al. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Intern Med 2017; 177:1461.</a></li><li><a class="nounderline abstract_t">Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161:1653.</a></li><li><a class="nounderline abstract_t">Quilliam BJ, Simeone JC, Ozbay AB. Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study. Clin Ther 2011; 33:1781.</a></li><li><a class="nounderline abstract_t">Misra-Hebert AD, Pantalone KM, Ji X, et al. Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015. Diabetes Care 2018; 41:1164.</a></li><li><a class="nounderline abstract_t">Davis TM, Brown SG, Jacobs IG, et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab 2010; 95:2240.</a></li><li><a class="nounderline abstract_t">Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002.</a></li><li><a class="nounderline abstract_t">UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50:1140.</a></li><li><a class="nounderline abstract_t">Gubitosi-Klug RA, Braffett BH, White NH, et al. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017; 40:1010.</a></li><li><a class="nounderline abstract_t">Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:271.</a></li><li><a class="nounderline abstract_t">Abraira C, Duckworth WC, Moritz T, VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2009; 11:150.</a></li><li><a class="nounderline abstract_t">Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.</a></li><li><a class="nounderline abstract_t">ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560.</a></li><li><a class="nounderline abstract_t">Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013; 98:3411.</a></li><li><a class="nounderline abstract_t">Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 2013; 36:3535.</a></li><li><a class="nounderline abstract_t">Zhong VW, Juhaeri J, Cole SR, et al. Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. J Clin Endocrinol Metab 2019; 104:1989.</a></li><li><a class="nounderline abstract_t">Seligman HK, Davis TC, Schillinger D, Wolf MS. Food insecurity is associated with hypoglycemia and poor diabetes self-management in a low-income sample with diabetes. J Health Care Poor Underserved 2010; 21:1227.</a></li><li><a class="nounderline abstract_t">Sarkar U, Karter AJ, Liu JY, et al. Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE). J Gen Intern Med 2010; 25:962.</a></li><li><a class="nounderline abstract_t">Berkowitz SA, Karter AJ, Lyles CR, et al. Low socioeconomic status is associated with increased risk for hypoglycemia in diabetes patients: the Diabetes Study of Northern California (DISTANCE). J Health Care Poor Underserved 2014; 25:478.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S158.</a></li><li><a class="nounderline abstract_t">International Hypoglycaemia Study Group. Minimizing Hypoglycemia in Diabetes. Diabetes Care 2015; 38:1583.</a></li><li><a class="nounderline abstract_t">Yeoh E, Choudhary P, Nwokolo M, et al. Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care 2015; 38:1592.</a></li><li><a class="nounderline abstract_t">de Zoysa N, Rogers H, Stadler M, et al. A psychoeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study. Diabetes Care 2014; 37:863.</a></li><li><a class="nounderline abstract_t">Iqbal A, Heller SR. The role of structured education in the management of hypoglycaemia. Diabetologia 2018; 61:751.</a></li><li><a class="nounderline abstract_t">Little SA, Speight J, Leelarathna L, et al. Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial. Diabetes Care 2018; 41:1600.</a></li><li><a class="nounderline abstract_t">Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014; 37:2114.</a></li><li><a class="nounderline abstract_t">Karter AJ, Parker MM, Moffet HH, et al. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. JAMA 2021; 325:2273.</a></li><li><a class="nounderline abstract_t">Torres Roldan VD, Urtecho M, Nayfeh T, et al. A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia. J Clin Endocrinol Metab 2023; 108:592.</a></li><li><a class="nounderline abstract_t">Simmons JH, Chen V, Miller KM, et al. Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. Diabetes Care 2013; 36:3573.</a></li><li><a class="nounderline abstract_t">Pogach L, Aron D. Balancing hypoglycemia and glycemic control: a public health approach for insulin safety. JAMA 2010; 303:2076.</a></li><li><a class="nounderline abstract_t">Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53:2079.</a></li><li><a class="nounderline abstract_t">Cryer PE. Elimination of hypoglycemia from the lives of people affected by diabetes. Diabetes 2011; 60:24.</a></li><li><a class="nounderline abstract_t">Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 2014; 63:2188.</a></li><li><a class="nounderline abstract_t">Guillod L, Comte-Perret S, Monbaron D, et al. Nocturnal hypoglycaemias in type 1 diabetic patients: what can we learn with continuous glucose monitoring? Diabetes Metab 2007; 33:360.</a></li><li><a class="nounderline abstract_t">REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ 2017; 356:j1285.</a></li><li><a class="nounderline abstract_t">Fatourechi MM, Kudva YC, Murad MH, et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94:729.</a></li><li><a class="nounderline abstract_t">Munshi MN, Slyne C, Segal AR, et al. Simplification of Insulin Regimen in Older Adults and Risk of Hypoglycemia. JAMA Intern Med 2016; 176:1023.</a></li><li><a class="nounderline abstract_t">Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42:1683.</a></li><li><a class="nounderline abstract_t">Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344:283.</a></li><li><a class="nounderline abstract_t">Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37:1265.</a></li><li><a class="nounderline abstract_t">Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43:1426.</a></li><li><a class="nounderline abstract_t">Lingenfelser T, Buettner U, Martin J, et al. Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM. Diabetes Care 1995; 18:321.</a></li><li><a class="nounderline abstract_t">Fritsche A, Stefan N, Häring H, et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134:729.</a></li><li><a class="nounderline abstract_t">Fanelli C, Pampanelli S, Lalli C, et al. Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on hypoglycemia awareness and counterregulation. Diabetes 1997; 46:1172.</a></li><li><a class="nounderline abstract_t">Cox DJ, Kovatchev B, Koev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med 2004; 11:212.</a></li><li><a class="nounderline abstract_t">Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 2017; 5:377.</a></li><li><a class="nounderline abstract_t">Rickels MR, DuBose SN, Toschi E, et al. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Care 2018; 41:1909.</a></li><li><a class="nounderline abstract_t">Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709.</a></li><li><a class="nounderline abstract_t">Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57:3169.</a></li><li><a class="nounderline abstract_t">Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia--a prospective population-based study. Exp Clin Endocrinol Diabetes 2003; 111:364.</a></li><li><a class="nounderline abstract_t">Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26:1902.</a></li><li><a class="nounderline abstract_t">Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol 1992; 11:135.</a></li><li><a class="nounderline abstract_t">Cox DJ, Gonder-Frederick L, Polonsky W, et al. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001; 24:637.</a></li><li><a class="nounderline abstract_t">Carlson JN, Schunder-Tatzber S, Neilson CJ, Hood N. Dietary sugars versus glucose tablets for first-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: a systematic review and meta-analysis. Emerg Med J 2017; 34:100.</a></li><li><a class="nounderline abstract_t">Cryer PE. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia 2009; 52:35.</a></li><li class="breakAll">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-severe-hypoglycemia-can-be-administered-without-injection (Accessed on July 29, 2019).</li><li><a class="nounderline abstract_t">Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016; 39:264.</a></li><li><a class="nounderline abstract_t">Valentine V, Newswanger B, Prestrelski S, et al. Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation. Diabetes Technol Ther 2019; 21:522.</a></li><li><a class="nounderline abstract_t">Beato-Víbora PI, Arroyo-Díez FJ. New uses and formulations of glucagon for hypoglycaemia. Drugs Context 2019; 8:212599.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212097s000lbl.pdf (Accessed on September 16, 2019).</li><li><a class="nounderline abstract_t">Li S, Hu Y, Tan X, et al. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes. Expert Opin Pharmacother 2020; 21:1311.</a></li><li><a class="nounderline abstract_t">Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care 2018; 41:531.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf (Accessed on April 14, 2021).</li><li><a class="nounderline abstract_t">Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care 2021.</a></li><li><a class="nounderline abstract_t">Haymond MW, Redondo MJ, McKay S, et al. Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study. Diabetes Care 2016; 39:465.</a></li><li><a class="nounderline abstract_t">Haymond MW, DuBose SN, Rickels MR, et al. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes. J Clin Endocrinol Metab 2017; 102:2994.</a></li><li><a class="nounderline abstract_t">Gunning RR, Garber AJ. Bioactivity of instant glucose. Failure of absorption through oral mucosa. JAMA 1978; 240:1611.</a></li><li><a class="nounderline abstract_t">Barennes H, Valea I, Nagot N, et al. Sublingual sugar administration as an alternative to intravenous dextrose administration to correct hypoglycemia among children in the tropics. Pediatrics 2005; 116:e648.</a></li><li><a class="nounderline abstract_t">Graz B, Dicko M, Willcox ML, et al. Sublingual sugar for hypoglycaemia in children with severe malaria: a pilot clinical study. Malar J 2008; 7:242.</a></li></ol></div><div id="topicVersionRevision">Topic 1805 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23589524" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23589524" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1797507" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404614" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypoglycemia, functional brain failure, and brain death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3290007" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477488" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27872155" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29162582" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078586" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35876660" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Consistent Effects of Hypoglycemia on Cognitive Function in People With or Without Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463040" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pseudohypoglycemia: a cause for unreliable finger-stick glucose measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18473690" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Accuracy of glycemic measurements in the critically ill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28616804" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hypoglycemic Event Frequency and the Effect of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27330125" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Design Considerations for Artificial Pancreas Pivotal Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29080929" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161418" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29459019" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29565719" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30089663" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259518" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388897" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026259" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26254702" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28828487" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387080" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19939489" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485213" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23731777" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33722700" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33550443" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The consequences of hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24144009" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923682" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Severe hypoglycemia predicts mortality in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30926258" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900314" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29127240" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20925543" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Severe hypoglycemia and risks of vascular events and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26961698" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25492401" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28222533" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23753199" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728302" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinically significant cognitive impairment in older adults with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35015886" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34078717" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of Type 1 Diabetes and Hypoglycemic and Hyperglycemic Events and Risk of Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476010" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term effect of diabetes and its treatment on cognitive function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554246" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246861" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk of Serious Trauma with Glucose-Lowering Drugs in Older Persons: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33860816" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32611607" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Severe Hypoglycemia and Risk of Falls in Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29892791" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Severe hypoglycemia is associated with high risk for falls in adults with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33888545" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence of bone fracture and its association with severe hypoglycemia in Japanese patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24615164" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28181728" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351086" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22646230" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23883381" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mechanisms of hypoglycemia-associated autonomic failure in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29618010" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hypoglycemic Exposure and Risk of Asymptomatic Hypoglycemia in Type 1 Diabetes Assessed by Continuous Glucose Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28828479" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11434798" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hypoglycemia in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018449" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29549082" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305006" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22111719" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Emergency hospitalizations for adverse drug events in older Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17415551" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550194" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9000705" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671796" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539917" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of intensive glucose lowering in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539916" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23760624" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900589" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30608562" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21099074" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Food insecurity is associated with hypoglycemia and poor diabetes self-management in a low-income sample with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20480249" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24858863" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low socioeconomic status is associated with increased risk for hypoglycemia in diabetes patients: the Diabetes Study of Northern California (DISTANCE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078590" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26207052" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Minimizing Hypoglycemia in Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26207053" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24319119" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A psychoeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28660491" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The role of structured education in the management of hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661916" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854041" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2×2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077502" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36477885" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026543" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20501929" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Balancing hypoglycemia and glycemic control: a public health approach for insulin safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20686748" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Intensified glucose lowering in type 2 diabetes: time for a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21193736" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Elimination of hypoglycemia from the lives of people affected by diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24962915" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652003" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Nocturnal hypoglycaemias in type 1 diabetic patients: what can we learn with continuous glucose monitoring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28360027" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19088167" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27273335" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Simplification of Insulin Regimen in Older Adults and Risk of Hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8405713" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7914259" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7895957" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7958494" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555474" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Improvement of impaired counterregulatory hormone response and symptom perception by short-term avoidance of hypoglycemia in IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11329230" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9200653" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on hypoglycemia awareness and counterregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657021" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126459" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Exercise management in type 1 diabetes: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29776987" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19088155" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033403" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The barrier of hypoglycemia in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520604" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Clinical characterisation of severe hypoglycaemia--a prospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766131" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Hypoglycemia in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1582382" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11315822" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Blood glucose awareness training (BGAT-2): long-term benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27644757" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Dietary sugars versus glucose tablets for first-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018509" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Preventing hypoglycaemia: what is the appropriate glucose alert value?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018509" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Preventing hypoglycaemia: what is the appropriate glucose alert value?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26681725" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31219349" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31402931" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : New uses and formulations of glucagon for hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31402931" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : New uses and formulations of glucagon for hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32267182" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273578" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273578" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33883196" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26861921" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591776" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/691147" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Bioactivity of instant glucose. Failure of absorption through oral mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263979" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Sublingual sugar administration as an alternative to intravenous dextrose administration to correct hypoglycemia among children in the tropics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19025610" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Sublingual sugar for hypoglycaemia in children with severe malaria: a pilot clinical study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
